DSIP vs Cerebrolysin
Both DSIP and Cerebrolysin are used for neuroprotection. Here's how their evidence, dosing, and regulatory status actually compare.
DSIP
Evidence CDelta Sleep-Inducing Peptide
A nonapeptide originally isolated from rabbit blood after EEG-defined slow-wave sleep induction. Inconsistent human evidence for sleep but explored for stress and analgesia.
View full DSIP profile →Cerebrolysin
Evidence BCerebrolysin (porcine brain peptide complex)
A standardized mixture of low-molecular-weight peptides from porcine brain. Decades of stroke, dementia, and TBI trial data — modest but consistent cognitive recovery effects.
View full Cerebrolysin profile →Side-by-Side
| Attribute | DSIP | Cerebrolysin |
|---|---|---|
| Evidence Grade | C | B |
| FDA Status | Not FDA-approved — research compound | Not FDA-approved in US — approved in 50+ countries for stroke, traumatic brain injury, and dementia |
| Typical Dose | 100–300 mcg before bed (subcutaneous) | Trial range: 5–30 mL daily (intravenous infusion) |
| Clinics Indexed | 38 | 41 |
| Categories | sleep, neuroprotection | cognitive, neuroprotection |
Key reported benefits — DSIP
- ✓Slow-wave-sleep signals (preclinical)
- ✓Stress/cortisol modulation
- ✓Possible analgesic effect
Key reported benefits — Cerebrolysin
- ✓Stroke recovery support
- ✓TBI rehabilitation
- ✓Cognitive function in dementia
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.